Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
In-licensing Search
Search the Pharmalicensing in-licensing directory by keyword. Alternatively our advanced search allows you to query by industry sector, therapeutic target and development phase.
Most Viewed
We are focused on licensing or acquiring new, late-stage technologies or existing prescription or OTC dermatology products More
Pharmaceuticals for osteoporosis and arthrosis; rx or OTC status More
Seeking opportunities for OTC consumer healthcare products in the area of oral and topical pain relief products. More
New Products/Technologies for Acne in early to late phases or already marketed required for acquisition or in-licensing for Mexico More
NCEs for innovative therapeutic targets in inflammatory/immunologic diseases. More
Recently Added
Seeking new technologies and/or existing products More
We are focused on licensing or acquiring new, late-stage technologies or existing prescription or OTC dermatology products More
Triton’s current portfolio includes women’s health (menopause) and urology (OAB and interstitial cystitis. More
products for gynecological disorders with OTC status More
We are looking for products to treat CNS disorders More
Help & Support
Find out how to use this section.
View the presentation.
View the presentation.
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Accident and Trauma
- Allergy
- Blood and forming organs
- Cardiovascular
- Central Nervous System
- Dermatological
- Endocrinology
- Gastrointestinal
- Genetic disorders
- Genito-urinary
- Hospital and Surgery
- Immune related disorders
- Infectious diseases
- Metabolism
- Musculoskeletal
- Oncology
- Oral Health
- Other therapeutic
- Respiratory
- Sensory organ
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
In the Spotlight...
Palau Pharma
Palau Pharma newly created biopharmaceutical company devoted to the discovery and development of small molecules for the treatment of inflammatory and autoimmune conditions
Based in Barcelona, Spain, Palau Pharma is the spin-out of GRUPO URIACH’s R&D Unit, the discoverer and developer of the antiplatelet agent Disgren®(trifusal), and the antihistaminic agent Rupafin®(rupatadine)
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us